Edition:
United States

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

13.94USD
22 May 2017
Change (% chg)

$0.01 (+0.07%)
Prev Close
$13.93
Open
$13.93
Day's High
$14.27
Day's Low
$13.78
Volume
21,181
Avg. Vol
29,525
52-wk High
$16.13
52-wk Low
$7.79

Latest Key Developments (Source: Significant Developments)

Oxford Immunotec posts Q1 loss per share of $0.36
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - Oxford Immunotec Global Plc :Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $-1.03 -- Thomson Reuters I/B/E/S.Reports first quarter 2017 financial results.Q1 loss per share $0.36.Sees q2 2017 revenue $24.9 million to $25.7 million.Q1 revenue $21.5 million versus i/b/e/s view $21.2 million.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Sees fy 2017 revenue $102 million to $105 million.Expect revenue to increase 21% to 24% for year using constant exchange rates.  Full Article

Oxford Immunotec Q4 loss per share $0.22
Tuesday, 28 Feb 2017 04:05pm EST 

Oxford Immunotec Global Plc : Oxford immunotec reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.22 . Sees q1 2017 revenue $20.8 million to $21.3 million . Q4 revenue $23.7 million versus i/b/e/s view $22.9 million . Sees fy 2017 revenue $102 million to $105 million . Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Fy2017 revenue view $105.1 million -- Thomson Reuters I/B/E/S .Q1 revenue view $22.6 million -- Thomson Reuters I/B/E/S.  Full Article

Oxford Immunotec Global files for a mixed shelf of up to $150 mln
Wednesday, 21 Dec 2016 05:48pm EST 

Oxford Immunotec Global Plc :Oxford Immunotec Global Plc - files for a mixed shelf of up to $150 million - SEC filing.  Full Article

Oxford Immunotec announces New England Journal of Medicine Publication on clinical trial results of serological and nucleic acid tests for babesia in blood screening
Thursday, 8 Dec 2016 07:00am EST 

Oxford Immunotec Global Plc :Oxford Immunotec announces New England Journal of Medicine Publication on clinical trial results of serological and nucleic acid tests for babesia in blood screening.  Full Article

Oxford Immunotec announces closing of $40 million in debt financing
Tuesday, 4 Oct 2016 04:24pm EDT 

Oxford Immunotec Global Plc : Oxford Immunotec announces closing of $40 million in debt financing . Says entered into an agreement with Midcap Financial that provides company with $40 million in debt financing . Says $40 million comprised of both a term loan and a revolving line of credit .Term loan of $30 million, revolving line of credit of up to $10 million both mature five years from closing.  Full Article

Oxford Immunotec Q2 loss per share $0.29
Tuesday, 2 Aug 2016 07:00am EDT 

Oxford Immunotec Global Plc : Q2 loss per share $0.29 . Sees fy 2016 revenue $82.5 million to $84.5 million . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Oxford Immunotec reports second quarter 2016 financial results . Sees Q3 2016 revenue $24.2 million to $25 million . Q2 revenue $19.2 million versus I/B/E/S view $18.1 million . FY 2016 revenue view $79.6 million -- Thomson Reuters I/B/E/S .Q3 revenue view $22.7 million -- Thomson Reuters I/B/E/S.  Full Article

Oxford Immunotec enters into definitive agreement to acquire Imugen
Thursday, 23 Jun 2016 04:05pm EDT 

Oxford Immunotec Global Plc : Deal for $22.2 million in an all cash transaction expected to close on July 1, 2016 . Expect acquisition of Imugen to contribute approximately $5.5 million in revenues in second half of 2016 . Deal for . Oxford Immunotec enters into definitive agreement to acquire Imugen . Raises expected revenues for calendar 2016 to between $79.5 and $82.5 million .Expect to have approximately $30 million of cash at end of 2016.  Full Article

Oxford Immunotec enters into definitive agreement to acquire Imugen Inc for $22.2 mln
Thursday, 23 Jun 2016 04:05pm EDT 

Oxford Immunotec Global Plc : Deal for $22.2 million . Deal for $22.2 million in an all cash transaction expected to close on july 1, 2016 . Expect acquisition of Imugen to contribute approximately $5.5 million in revenues in second half of 2016 . Oxford Immunotec enters into definitive agreement to acquire Imugen . Raises expected revenues for calendar 2016 to between $79.5 and $82.5 million .Expect to have approximately $30 million of cash at end of 2016.  Full Article

Oxford Immunotec Global PLC gives Q2, FY 2016 revenue guidance
Tuesday, 3 May 2016 07:00am EDT 

Oxford Immunotec Global PLC:Expects Q2 2016 revenue of between $17.4-$18.2 mln.Expects FY 2016 revenue of between $74-$77 mln.  Full Article

Oxford Immunotec Global PLC announces CE Mark for T-SPOT.PRT Test
Tuesday, 22 Dec 2015 04:45pm EST 

Oxford Immunotec Global PLC:Says gained CE marking for the T-SPOT PRT test.  Full Article

More From Around the Web